Source: Annual Congress 2001 - Mesothelioma, malignant pleural effusions and rare thoracic tumours
Disease area: Pulmonary vascular diseases, Respiratory infections, Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
R. Jankowska, I. Porebska, T. Dyla, W. Szeliga (Wroclaw, Poland). Vascular endothelial growth factor (VEGF) in malignant and tuberculous pleural effusions. Eur Respir J 2001; 16: Suppl. 31, 2709

Member's Comments

No comment yet.

Related content which might interest you: The role of vascular endothelial growth factor in tuberculous and parapneumonic pleural effusions Source: Annual Congress 2008 - Pleural diseases and interventions Year: 2008 The diagnostic value of vascular endothelial growth factor in pleural effusion Source: Eur Respir J 2004; 24: Suppl. 48, 246s Year: 2004 Vascular endothelial growth factor in pleural effusions of different origin Source: Eur Respir J 2005; 25: 600-604 Year: 2005 Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma Source: Eur Respir J 2008; 32: 924-930 Year: 2008 Profibrotic implication of platelet-activating factor in tuberculous pleural effusion Source: Virtual Congress 2020 – Translational therapeutic advances Year: 2020 Talc mediates angiostasis in malignant pleural effusions via endostatin induction Source: Eur Respir J 2007; 29: 761-769 Year: 2007 Is pleural VEGF a useful parameter? Source: Annual Congress 2007 - Pleural malignancy Year: 2007 Interleukin-8 and other mediators are related to tumour burden in malignant pleural effusions (MPE) Source: Eur Respir J 2007; 30: Suppl. 51, 103s Year: 2007 Diagnostic value of vascular endothelial growth factor, glycosaminoglycan, cathepsin S, cathepsin H in the discrimination of transudate exudate and benign malignant patients with pleural effusion Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions Year: 2012 Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis Source: Eur Respir Rev 2012 21:196-206 Year: 2012 The clininical value of vascular endothelial growth factor (VEGF) in the development of lung sarcoidosis. Source: International Congress 2018 – Sarcoidosis: from basic research to patient outcomes Year: 2018 Predictive value of pro-inflammatory cytokine and pro-angiogenic factor in differentiating malignant from benign exudative effusion Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Diagnostic value of pleural fluid angiopoietin-2 (Ang-2) levels, to differentiate malignant pleural effusions from benign pleural effusions Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma Source: Eur Respir J 2010; 36: 1099-1105 Year: 2010 Epidermal growth factor in the lungs of infants developing chronic lung disease Source: Eur Respir J 2001; 18: 796-800 Year: 2001 The value of IL6 in differentiation between malignant and non malignant pleural effusion Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009 Increased expression of angiogenic growth factor stromal cell derived factor-1 (SDF-1/CXCL12) in pleural fluid of patients with lung cancer: preliminary results Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008 Can VEGF be used in differential diagnosis of pleural effusions? Source: Eur Respir J 2007; 30: Suppl. 51, 565s Year: 2007 Increased vascular endothelial growth factor in acute eosinophilic pneumonia Source: Eur Respir J 2003; 21: 774-778 Year: 2003 Tumour necrosis correlates with angiogenesis and is a prognostic factor in malignant mesothelioma Source: Eur Respir J 2002; 20: Suppl. 38, 232s Year: 2002